Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Genomic Vision Raises EUR 4 Million in Series B Financing

Abstract:
Genomic Vision, a developer of novel diagnostic and drug discovery solutions based on its world-leading nanotechnology for DNA analysis in the areas of cancer and acute diseases, announced today that it has raised EUR 4 million (approx. USD 6.3 million) in a series B financing round. New investor Vesalius BioCapital joined existing investor Societe Generale Asset Management Alternative Investments (SGAM AI). This round brings the total capital invested to EUR 6 million since Genomic Vision's creation in July 2004.

Genomic Vision Raises EUR 4 Million in Series B Financing

PARIS, France | Posted on July 24th, 2008

The funds will be used to expand Genomic Vision's in-house R&D programs and automation, as well as strengthen the firm's ongoing collaborative programs with partners. "We are delighted to work with financial partners who fully understand and stay informed about our diagnostic and drug discovery activities in the areas of cancer and genetic diseases," said Aaron Bensimon, founder, president and CEO of Genomic Vision. "It is particularly rewarding to have SGAM AI renew their confidence in us after investing three years ago. We are pleased to have attracted Vesalius BioCapital, biotechnology entrepreneurial specialists whose skill and experience will be very useful. This support from our investors will help us to develop our products and services more quickly and enable us to take advantage of growing market opportunities."

"Genomic Vision has a unique technology, Molecular Combing, capable of revolutionizing several diagnostic approaches and DNA analysis," said Jean-Yves Nothias, Managing Partner, BioConvergence team of SGAM AI. "We believe very strongly that their genomic tests will be useful for cancers, genetic diseases, viral diseases and many other applications with wide potential markets."

"We are excited about Genomic Vision's capabilities, which have a significant potential to complete the technical developments required for the use of its molecular combing technology for early cancer diagnosis," said StÚphane Verdood, Partner of Vesalius BioCapital.

In a move to enhance the company's development, Genomic Vision recently transferred its operations to Paris SantÚ Cochin, an innovative healthcare Biotech Park, reputed for its excellent working conditions for early stage biotech firms around the Paris region. Genomic Vision now employs 15 people, carries out its operations in 600m2 (6000 sq ft approx), and benefits from the support and know-how of the Paris Biotech SantÚ network. Legal advisors for the fund raising were Philippe Simon, KGA, representing Genomic Vision, Hubert Segain from Herbert Smith representing Vesalius BioCapital Venture, and Mickael LÚvy representing SGAM AI.

About Genomic Vision Genomic Vision develops novel diagnostic and drug discovery solutions based on its world-leading nanotechnology for DNA analysis in the areas of cancer and acute diseases. The company uses a powerful technique, Molecular Combing Technology, for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. Genomic Vision holds an exclusive license for the technology from the Pasteur Institute.

Genomic Vision works through partnerships and alliances with the diagnostic and pharmaceutical industries to distribute its tests and services. The company is focused on three key areas: - Diagnostics: the discovery of genomic biomarkers and the development of DNA-based diagnostic tests for early disease identification and management - Drug Development: exploiting the Combing Replication Assay to test the efficacy of lead compounds by studying DNA replication in proliferating cancer cells - Drug Response Biomarkers: the analysis and identification of the genomic region in the human genome to allow the characterization of genetic differences between individuals who respond differently to the same drug

####

About Genomic Vision
Genomic Vision's headquarters and biological research facilities are Paris SantÚ Cochin, France. The company is supported by a network of collaborations with leading academic researchers and clinicians. The company has raised EUR 6 since its creation in 2004.

For more information, please click here

Contacts:
Andrew Lloyd & Associates
Andrew Lloyd / Neil Hunter
Tel: +44 1273 675100
/


Upesh Mistry
ANDREW LLOYD & ASSOCIATES www.ala.com


Brighton Business Centre
95 Ditchling Road
Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100
Fax: +44 1273 675400

55 rue Boissonade
75014 Paris FRANCE
Tel: +33 1 56 54 07 00
Fax: +33 1 56 54 07 01

Copyright © Genomic Vision

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Promising Step Taken in Iran towards Treatment of Spinal Cord Injury August 3rd, 2015

Diagnosis of Salmonella Bacterium-Caused Food Poisoning by Biosensors August 3rd, 2015

Thin films offer promise for ferroelectric devices: Researchers at Tokyo Institute of Technology demystify the ferroelectric properties observed in hafnium-oxide-based thin films, revealing a potentially useful device material August 3rd, 2015

Kalam: versatility personified August 1st, 2015

The National Space Society Pays Tribute to Dr. Kalam -- One Of Our Leading Lights Has Joined The Stars August 1st, 2015

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Portfolio Company, HZO, Announces Partnerships with Dell and Motorola August 1st, 2015

Harris & Harris Group Portfolio Company, Bridgelux, Enters into Agreement to be Acquired by an Investment Group July 22nd, 2015

Nanomedicine

Promising Step Taken in Iran towards Treatment of Spinal Cord Injury August 3rd, 2015

Diagnosis of Salmonella Bacterium-Caused Food Poisoning by Biosensors August 3rd, 2015

Gold-diamond nanodevice for hyperlocalised cancer therapy: Gold nanorods can be used as remote controlled nanoheaters delivering the right amount of thermal treatment to cancer cells, thanks to diamond nanocrystals used as temperature sensors August 1st, 2015

Heating and cooling with light leads to ultrafast DNA diagnostics July 31st, 2015

Announcements

Promising Step Taken in Iran towards Treatment of Spinal Cord Injury August 3rd, 2015

Diagnosis of Salmonella Bacterium-Caused Food Poisoning by Biosensors August 3rd, 2015

Thin films offer promise for ferroelectric devices: Researchers at Tokyo Institute of Technology demystify the ferroelectric properties observed in hafnium-oxide-based thin films, revealing a potentially useful device material August 3rd, 2015

Advances and Applications in Biosensing, Sensor Power, and Sensor R&D to be Covered at Sensors Global Summit August 1st, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project